Analyst Price Targets — SYK
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 13, 2026 11:20 am | — | BTIG | $371.00 | $329.78 | TheFly | Stryker price target lowered to $371 from $379 at BTIG |
| July 9, 2026 1:22 pm | — | Argus Research | $370.00 | $328.79 | TheFly | Stryker price target raised to $370 from $350 at Argus |
| July 8, 2026 8:26 pm | — | BMO Capital | $369.00 | $326.85 | TheFly | Stryker initiated with an Outperform at BMO Capital |
| July 6, 2026 12:48 pm | — | Evercore ISI | $350.00 | $319.22 | TheFly | Stryker price target lowered to $350 from $355 at Evercore ISI |
| June 5, 2026 9:16 am | Mike Kratky | Leerink Partners | $407.00 | $301.21 | StreetInsider | Stryker (SYK) PT Lowered to $407 at Leerink |
| May 4, 2026 1:39 pm | Richard Newitter | Truist Financial | $330.00 | $293.44 | TheFly | Stryker price target lowered to $330 from $380 at Truist |
| May 4, 2026 9:27 am | Matt Miksic | Barclays | $394.00 | $294.73 | TheFly | Stryker price target lowered to $394 from $469 at Barclays |
| May 1, 2026 11:43 pm | David Roman | Goldman Sachs | $361.00 | $294.73 | TheFly | Stryker price target raised to $361 from $357 at Goldman Sachs |
| May 1, 2026 1:10 pm | — | Bernstein | $410.00 | $302.38 | TheFly | Stryker price target lowered to $410 from $465 at Bernstein |
| May 1, 2026 12:53 pm | — | Robert W. Baird | $385.00 | $307.87 | TheFly | Stryker price target lowered to $385 from $437 at Baird |
Latest News for SYK
SYK launches Mako RPS, expanding into handheld robotics for total knee replacement and broadening access to robotic-assisted orthopedic procedures.
New handheld robotic technology expands the Mako platform and brings Mako robotic-assisted knee replacement to a new segment of the orthopaedic market Stryker announced the U.S. commercial launch of Mako RPS (Robotic Power System) for total knee replacement procedures. The launch introduces Mako Handheld Robotics, expanding the Mako portfolio beyond robotic-arm assisted surgery.
Stryker remains a high-quality MedTech compounder despite a rare Q1 miss driven by a temporary cyber disruption. Q1 weakness was not demand-driven; full-year guidance is unchanged and end-market demand remains healthy. Current valuation reflects temporary disruption, offering a more attractive entry into SYK, though the stock is not cheap.
Rising use of automation in healthcare is reshaping robotics ETFs as med-tech innovators gain prominence.
Investors looking for stocks in the Medical - Products sector might want to consider either ICU Medical (ICUI) or Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.